Accelerating Oncology Denial Appeal Automation

Klivira's platform delivers robust oncology denial appeal automation, addressing the intricate challenges of cancer care prior authorizations and accelerating revenue recovery.

Oncology prior authorizations are among the most complex in healthcare, often involving high-cost biologics, infusion therapy, and frequent regimen changes. Denials in this specialty critically impact patient care timelines and financial performance, necessitating an efficient and precise appeal process.

The Unique Challenges of Oncology PA Denials

Oncology prior authorizations are characterized by high volume and clinical complexity, spanning chemotherapy regimens, biologics, radiation therapy, and advanced imaging. Denials frequently stem from intricate medical necessity criteria, often tied to NCCN Clinical Practice Guidelines, or from documentation gaps that delay critical cancer treatments.

Common Triggers for Oncology PA Denials

Off-label use lacking NCCN Compendium support for specific tumor types or lines of therapy.
Payer-mandated step therapy requirements for biologics or oral oncolytics.
Documentation gaps, such as missing pathology reports, molecular markers (e.g., EGFR, ALK, PD-L1), or prior-line treatment responses.
Site-of-service mismatches for infusion therapies (e.g., HOPD vs. home infusion).
Non-coverage based on National/Local Coverage Determinations (NCDs/LCDs) for Medicare Advantage plans.

Klivira's Automated Appeal Workflow for Oncology

Klivira's platform automates the entire denial appeal process, beginning with intelligent denial classification using normalized CARC/RARC taxonomy. This ensures each oncology denial, whether for a J-code biologic or an oral oncolytic, is routed to the correct appeal pathway, factoring in payer-specific requirements and timely-filing windows.

Precision in Oncology Appeal Letter Generation

**FHIR-based documentation re-discovery**: Automatically pulls additional clinical evidence from the EMR, including new notes, labs, or imaging results, crucial for justifying complex oncology regimens.
**NCCN-compendium-aware templates**: Composes appeal letters using payer-specific templates, incorporating relevant NCCN guidelines and compendium citations for off-label drug use.
**Clinician review for clinical necessity**: Drafts clinician-reviewable letters for complex clinical-necessity appeals, allowing oncologists to approve or edit before submission.
**Medical vs. Pharmacy Benefit Split**: Routes appeals appropriately for medical benefit (IV infusions via X12 278 or payer portal) and pharmacy benefit (oral oncolytics via PBMs or ePA partners).

Accelerating Time-to-Treatment and Revenue Recovery

For oncology, PA delays directly impact patient outcomes, particularly given the urgency of many cancer diagnoses. Automated appeal processing significantly reduces administrative burden and accelerates approvals for high-cost treatments like chemotherapy, immunotherapy, and radiation therapy. Klivira ensures timely submission, tracks appeal status, and captures outcomes to streamline downstream billing and payment reprocessing, mitigating financial risk.

Integrated Peer-to-Peer Scheduling and Feedback Loops

Many clinical-necessity denials in oncology escalate to peer-to-peer review. Klivira integrates peer-to-peer scheduling, optimizing oncologist availability for these critical discussions. Furthermore, successful appeal patterns by denial reason and payer feed back into upstream PA submission processes, continuously improving initial approval rates for complex oncology cases.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefit denials in oncology appeals?

Klivira's platform is designed to recognize the benefit split for oncology drugs. It routes medical benefit appeals (e.g., J-coded IV infusions) through the payer's medical PA channel, often via provider portals or X12 278, and pharmacy benefit appeals (e.g., oral oncolytics) through the payer's PBM and ePA partners, ensuring the correct pathway is always utilized.

Can Klivira automatically pull clinical documentation specific to oncology for appeals?

Yes. Klivira leverages FHIR-based integration to re-discover and pull relevant clinical documentation from the EMR. This includes pathology reports, molecular marker results (like EGFR, ALK, PD-L1), prior-line treatment responses, and performance status (ECOG/Karnofsky scores), which are critical for substantiating oncology appeals.

How does Klivira ensure appeal letters are aligned with NCCN guidelines for oncology?

Klivira's system incorporates NCCN-compendium-aware policy logic. When generating appeal letters for clinical-necessity denials, it uses payer-specific templates that can cite NCCN Clinical Practice Guidelines and the NCCN Drugs & Biologics Compendium, particularly for off-label uses, ensuring evidence-grounded submissions.

What types of oncology PA denials are most effectively addressed by automation?

Automation is highly effective for denials related to documentation gaps, step therapy requirements, site-of-service mismatches, and off-label use without sufficient compendium support. While novel clinical judgment denials still require human oversight, automated systems significantly streamline the initial appeal stages for common, recurring issues.

Does Klivira help with peer-to-peer scheduling for oncology appeals?

Yes, Klivira integrates peer-to-peer scheduling capabilities. This helps coordinate critical reviews between oncologists and payer medical directors for clinical-necessity denials, optimizing the notoriously challenging availability of clinicians for these time-sensitive discussions.